Adult patients with COVID-19 develop a thrombotic coagulopathy, and
numerous series have reported high rates of venous thromboembolism
(VTE), including deep vein thromboses (DVT) and pulmonary embolism
(PE).1, 2 However, the adult cohorts have median ages
of 63-64 years. Limited data have been presented on pediatric cohorts
with COVID-19, and an associated coagulopathy has not been well
described.7-10 In particular, whether an aggressive
anticoagulation strategy, as has been implemented in many medical
centers, is necessary, effective or safe for children is not clear.
Defining the clinical characteristics and severity of the coagulopathy
of COVID-19 in pediatric patients is an urgent need. In this context, we
performed a single-site retrospective review of 54 patients ages 2
months to 30 years, with confirmed COVID-19 at a single Children’s
Hospital in the Bronx, New York. We describe the coagulopathy associated
with COVID-19 in children and young adults and how these data informed
the iterative process that led to the development of our institutional
anticoagulation guidelines.